Tags

Type your tag names separated by a space and hit enter

Cytoprotective and Neurotrophic Effects of Octadecaneuropeptide (ODN) in in vitro and in vivo Models of Neurodegenerative Diseases.
Front Endocrinol (Lausanne). 2020; 11:566026.FE

Abstract

Octadecaneuropeptide (ODN) and its precursor diazepam-binding inhibitor (DBI) are peptides belonging to the family of endozepines. Endozepines are exclusively produced by astroglial cells in the central nervous system of mammals, and their release is regulated by stress signals and neuroactive compounds. There is now compelling evidence that the gliopeptide ODN protects cultured neurons and astrocytes from apoptotic cell death induced by various neurotoxic agents. In vivo, ODN causes a very strong neuroprotective action against neuronal degeneration in a mouse model of Parkinson's disease. The neuroprotective activity of ODN is based on its capacity to reduce inflammation, apoptosis, and oxidative stress. The protective effects of ODN are mediated through its metabotropic receptor. This receptor activates a transduction cascade of second messengers to stimulate protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) signaling pathways, which in turn inhibits the expression of proapoptotic factor Bax and the mitochondrial apoptotic pathway. In N2a cells, ODN also promotes survival and stimulates neurite outgrowth. During the ODN-induced neuronal differentiation process, numerous mitochondria and peroxisomes are identified in the neurites and an increase in the amount of cholesterol and fatty acids is observed. The antiapoptotic and neurotrophic properties of ODN, including its antioxidant, antiapoptotic, and pro-differentiating effects, suggest that this gliopeptide and some of its selective and stable derivatives may have therapeutic value for the treatment of some neurodegenerative diseases.

Authors+Show Affiliations

Laboratory of Neurophysiology Cellular Physiopathology and Biomolecule Valorisation, LR18ES03, Faculty of Sciences of Tunis, University Tunis El Manar, Tunis, Tunisia.Laboratory of Neurophysiology Cellular Physiopathology and Biomolecule Valorisation, LR18ES03, Faculty of Sciences of Tunis, University Tunis El Manar, Tunis, Tunisia. Team Bio-PeroxIL, Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism/University Bourgogne Franche-Comté (UBFC)/Inserm, Dijon, France.Laboratory of Neurophysiology Cellular Physiopathology and Biomolecule Valorisation, LR18ES03, Faculty of Sciences of Tunis, University Tunis El Manar, Tunis, Tunisia.Laboratory of Neurophysiology Cellular Physiopathology and Biomolecule Valorisation, LR18ES03, Faculty of Sciences of Tunis, University Tunis El Manar, Tunis, Tunisia. Normandy University, Neuronal and Neuroendocrine Differentiation and Communication, Inserm U1239, Rouen, France.Laboratory of Neurophysiology Cellular Physiopathology and Biomolecule Valorisation, LR18ES03, Faculty of Sciences of Tunis, University Tunis El Manar, Tunis, Tunisia.Normandy University, Neuronal and Neuroendocrine Differentiation and Communication, Inserm U1239, Rouen, France.Normandy University, Neuronal and Neuroendocrine Differentiation and Communication, Inserm U1239, Rouen, France. Normandy University, Regional Platform for Cell Imaging of Normandy (PRIMACEN), Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.Normandy University, Neuronal and Neuroendocrine Differentiation and Communication, Inserm U1239, Rouen, France. Normandy University, Regional Platform for Cell Imaging of Normandy (PRIMACEN), Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.Laboratory of Neurophysiology Cellular Physiopathology and Biomolecule Valorisation, LR18ES03, Faculty of Sciences of Tunis, University Tunis El Manar, Tunis, Tunisia.Normandy University, Neuronal and Neuroendocrine Differentiation and Communication, Inserm U1239, Rouen, France.Team Bio-PeroxIL, Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism/University Bourgogne Franche-Comté (UBFC)/Inserm, Dijon, France.Normandy University, Neuronal and Neuroendocrine Differentiation and Communication, Inserm U1239, Rouen, France. Normandy University, Regional Platform for Cell Imaging of Normandy (PRIMACEN), Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33250858

Citation

Masmoudi-Kouki, Olfa, et al. "Cytoprotective and Neurotrophic Effects of Octadecaneuropeptide (ODN) in in Vitro and in Vivo Models of Neurodegenerative Diseases." Frontiers in Endocrinology, vol. 11, 2020, p. 566026.
Masmoudi-Kouki O, Namsi A, Hamdi Y, et al. Cytoprotective and Neurotrophic Effects of Octadecaneuropeptide (ODN) in in vitro and in vivo Models of Neurodegenerative Diseases. Front Endocrinol (Lausanne). 2020;11:566026.
Masmoudi-Kouki, O., Namsi, A., Hamdi, Y., Bahdoudi, S., Ghouili, I., Chuquet, J., Leprince, J., Lefranc, B., Ghrairi, T., Tonon, M. C., Lizard, G., & Vaudry, D. (2020). Cytoprotective and Neurotrophic Effects of Octadecaneuropeptide (ODN) in in vitro and in vivo Models of Neurodegenerative Diseases. Frontiers in Endocrinology, 11, 566026. https://doi.org/10.3389/fendo.2020.566026
Masmoudi-Kouki O, et al. Cytoprotective and Neurotrophic Effects of Octadecaneuropeptide (ODN) in in Vitro and in Vivo Models of Neurodegenerative Diseases. Front Endocrinol (Lausanne). 2020;11:566026. PubMed PMID: 33250858.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytoprotective and Neurotrophic Effects of Octadecaneuropeptide (ODN) in in vitro and in vivo Models of Neurodegenerative Diseases. AU - Masmoudi-Kouki,Olfa, AU - Namsi,Amira, AU - Hamdi,Yosra, AU - Bahdoudi,Seyma, AU - Ghouili,Ikram, AU - Chuquet,Julien, AU - Leprince,Jérôme, AU - Lefranc,Benjamin, AU - Ghrairi,Taoufik, AU - Tonon,Marie-Christine, AU - Lizard,Gérard, AU - Vaudry,David, Y1 - 2020/11/04/ PY - 2020/05/26/received PY - 2020/08/28/accepted PY - 2020/11/30/entrez PY - 2020/12/1/pubmed PY - 2021/5/22/medline KW - cell differentiation KW - cell protection KW - gliopeptide ODN KW - neurodegeneration KW - oxidative stress SP - 566026 EP - 566026 JF - Frontiers in endocrinology JO - Front Endocrinol (Lausanne) VL - 11 N2 - Octadecaneuropeptide (ODN) and its precursor diazepam-binding inhibitor (DBI) are peptides belonging to the family of endozepines. Endozepines are exclusively produced by astroglial cells in the central nervous system of mammals, and their release is regulated by stress signals and neuroactive compounds. There is now compelling evidence that the gliopeptide ODN protects cultured neurons and astrocytes from apoptotic cell death induced by various neurotoxic agents. In vivo, ODN causes a very strong neuroprotective action against neuronal degeneration in a mouse model of Parkinson's disease. The neuroprotective activity of ODN is based on its capacity to reduce inflammation, apoptosis, and oxidative stress. The protective effects of ODN are mediated through its metabotropic receptor. This receptor activates a transduction cascade of second messengers to stimulate protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) signaling pathways, which in turn inhibits the expression of proapoptotic factor Bax and the mitochondrial apoptotic pathway. In N2a cells, ODN also promotes survival and stimulates neurite outgrowth. During the ODN-induced neuronal differentiation process, numerous mitochondria and peroxisomes are identified in the neurites and an increase in the amount of cholesterol and fatty acids is observed. The antiapoptotic and neurotrophic properties of ODN, including its antioxidant, antiapoptotic, and pro-differentiating effects, suggest that this gliopeptide and some of its selective and stable derivatives may have therapeutic value for the treatment of some neurodegenerative diseases. SN - 1664-2392 UR - https://www.unboundmedicine.com/medline/citation/33250858/Cytoprotective_and_Neurotrophic_Effects_of_Octadecaneuropeptide__ODN__in_in_vitro_and_in_vivo_Models_of_Neurodegenerative_Diseases_ DB - PRIME DP - Unbound Medicine ER -